Cargando…
Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease
Sodium–glucose cotransporter 2 (SGLT2) occurs in the proximal renal tubule cells. We investigate the hepatic expression of SGLT2 and its related factors in patients with chronic liver disease. This is a retrospective human study. The liver tissues were biopsied from patients with chronic liver disea...
Autores principales: | Nakano, Dan, Akiba, Jun, Tsutsumi, Tsubasa, Kawaguchi, Machiko, Yoshida, Takafumi, Koga, Hironori, Kawaguchi, Takumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606064/ https://www.ncbi.nlm.nih.gov/pubmed/36131166 http://dx.doi.org/10.1007/s00795-022-00334-9 |
Ejemplares similares
-
Effects of SGLT2 inhibitor on tumor‐releasing chemokines/cytokines in Hep3B and Huh7 cells
por: Nakano, Dan, et al.
Publicado: (2022) -
The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017) -
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes, Bryce C, et al.
Publicado: (2019) -
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023) -
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)